These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 9076625

  • 1. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E, Mizokami M, Suzuki K, Ohba KI, Ohno T, Mizuno M, Iijima Y, Saito H, Nemoto A, Nukuta N.
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [Abstract] [Full Text] [Related]

  • 2. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
    Mizokami M, Orito E, Gibo Y, Suzuki K, Ohba K, Ohno T, Lau JY.
    Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T.
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S, Suzuki F, Hosaka T, Akuta N, Someya T, Kobayashi M, Tsubota A, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [Abstract] [Full Text] [Related]

  • 9. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S.
    Ann Intern Med; 1997 Nov 15; 127(10):875-81. PubMed ID: 9382365
    [Abstract] [Full Text] [Related]

  • 10. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
    Picciotto A, Campo N, Brizzolara R, Sinelli N, Poggi G, Grasso S, Celle G.
    Eur J Gastroenterol Hepatol; 1997 Jan 15; 9(1):67-9. PubMed ID: 9031902
    [Abstract] [Full Text] [Related]

  • 11. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, Hayashi K, Kato K, Iino S, Lau JY.
    J Med Virol; 1995 Jun 15; 46(2):109-15. PubMed ID: 7636496
    [Abstract] [Full Text] [Related]

  • 12. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.
    Kakumu S, Yoshika K, Tanaka K, Higashi Y, Kurokawa S, Hirofuji H, Kusakabe A.
    J Med Virol; 1993 Sep 15; 41(1):65-70. PubMed ID: 8228941
    [Abstract] [Full Text] [Related]

  • 13. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G, Ciancio A, Ghisetti V, Rocca G, Cariti G, Andreoni M, Tabone M, Roffi L, Calleri G, Ballaré M, Terreni N, Sartori M, Tappero GF, Traverso A, Poggio A, Orani A, Maggi G, Di Napoli A, Arrigoni A, Rizzetto M, North West Italian Hepatological Group.
    Eur J Gastroenterol Hepatol; 2001 Feb 15; 13(2):149-55. PubMed ID: 11246614
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S, Okusa T, Araki A, Fujiki K, Takashimizu I, Okayasu I, Yamamoto N, Sato C.
    J Med Virol; 1995 Jul 15; 46(3):265-8. PubMed ID: 7561801
    [Abstract] [Full Text] [Related]

  • 17. Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial.
    Bresters D, Cuypers HT, Reesink HW, Mauser-Bunschoten EP, van den Berg HM, Schaasberg WP, Wilber JC, Urdea MS, Neuwald P, Lelie PN.
    J Med Virol; 1994 Jul 15; 43(3):262-8. PubMed ID: 7931188
    [Abstract] [Full Text] [Related]

  • 18. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, Grünewald K, Patsch J.
    Dig Dis Sci; 1996 Dec 15; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.
    Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, Yamada Y, Abe H.
    Scand J Gastroenterol; 1994 Nov 15; 29(11):1039-43. PubMed ID: 7871371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.